% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tasdogan:300249,
      author       = {A. Tasdogan$^*$ and R. J. Sullivan and A. Katalinic and C.
                      Lebbe and D. Whitaker and S. Puig and L. V. van de
                      Poll-Franse and D. Massi and D. Schadendorf$^*$},
      title        = {{C}utaneous melanoma.},
      journal      = {Nature reviews / Disease Primers},
      volume       = {11},
      number       = {1},
      issn         = {2056-676X},
      address      = {Basingstoke},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2025-00710},
      pages        = {23},
      year         = {2025},
      abstract     = {Cutaneous melanoma is a common cancer in Australia and New
                      Zealand, Europe, and North America, and its incidence is
                      still increasing in many regions. Ultraviolet (UV) radiation
                      exposure (for example, through excessive sunlight exposure)
                      remains the primary risk factor for melanoma; however,
                      public awareness campaigns have led to a marked reduction in
                      mortality. In addition to genetic damage from UV radiation,
                      specific genetic alterations have been linked to melanoma.
                      The stage of the tumour at the time of diagnosis is of
                      greater importance for melanoma prognosis than in almost any
                      other cancer. Context-dependent genetic mutations that
                      attenuate tumour-suppressive mechanisms or activate
                      growth-promoting signalling pathways are crucial factors in
                      the development of cutaneous melanoma. In addition to
                      external factors such as UV radiation, the tumour
                      microenvironment can contribute to melanoma progression,
                      invasion and metastasis. Cutaneous melanoma treatment has
                      improved considerably over the past decade with the
                      discovery and development of immune checkpoint inhibitors
                      and therapy targeting BRAF and MEK. Over the next decade,
                      several priorities are likely to influence melanoma research
                      and management, including the continued advance of precision
                      medicine methods to identify the most suitable patients for
                      the most effective treatment, with the aim of improving
                      clinical outcomes.},
      subtyp        = {Review Article},
      keywords     = {Humans / Melanoma: epidemiology / Melanoma: therapy /
                      Melanoma: diagnosis / Melanoma: physiopathology / Melanoma:
                      etiology / Skin Neoplasms: epidemiology / Skin Neoplasms:
                      therapy / Skin Neoplasms: diagnosis / Skin Neoplasms:
                      physiopathology / Ultraviolet Rays: adverse effects /
                      Melanoma, Cutaneous Malignant / Risk Factors / Australia:
                      epidemiology / Prognosis},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40180935},
      doi          = {DOI:10.1038/s41572-025-00603-8},
      url          = {https://inrepo02.dkfz.de/record/300249},
}